EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A)

Anshumali Mittal, Matthew F Martin iD, Laurent Provins, Adrian Hall iD, Marie Ledecq, Christian Wolff, Michel Gillard, Peter S Horanyi iD, Jonathan A Coleman iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2510239122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Anshumali Mittal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA 15213. Hauptthemen laut MEDLINE: Anticonvulsants, Membrane Glycoproteins, Nerve Tissue Proteins, Pyrrolidinones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Brain and Behavior Research Foundation (BBRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brivaracetam (BRV) and levetiracetam (LEV) are antiseizure medications (ASMs); UCB-J is a PET tracer targeting synaptic vesicle protein 2A (SV2A); UCB7361 is closely related to padsevonil, an experimental anticonvulsant; while UCB1244283 acts as an allosteric modulator for BRV and LEV binding but not for these other ligands. The SV2A-BRV-UCB1244283 structure reveals how UCB1244283 allosterically enhances BRV binding by occupying an allosteric site near the primary binding site, preventing BRV dissociation. This allosteric site, formed by hydrophobic and uncharged residues, is an uncharacterized small-molecule binding site in SV2A. Structural analysis and mutagenesis demonstrate that an allosteric network between the primary and allosteric sites governs high-affinity ASM binding. Our studies suggest that UCB1244283 selectively binds SV2A over SV2B and SV2C, with specific mutations disrupting binding. Structures of SV2A-UCB-J and SV2A-UCB7361 show that UCB1244283 binding is only possible when the primary site ligand does not overlap with the allosteric site, and that repositioning of Ser601, Thr605, and Leu655 is critical for allosteric ligand binding. Structural comparison of multiple SV2A complexes reveals that primary site occupancy shapes the conformation of the lumenal half of the transmembrane domain, influencing how UCB1244283 binds via a connected network that differentially stabilizes TM1 in either an open or closed conformation and repositions key allosteric and primary site residues. These insights provide a foundation for developing therapeutics targeting the allosteric site and modulating SV2A function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsMembrane GlycoproteinsNerve Tissue ProteinsPyrrolidinonesAllosteric RegulationLevetiracetamHumansAnimalsAllosteric SiteProtein BindingBinding Sites

Stichwörter der Autor:innen

allosterymembrane proteinpharmacologystructural biology

Substanzen

AnticonvulsantsMembrane GlycoproteinsNerve Tissue ProteinsSV2A protein, humanLevetiracetambrivaracetamPyrrolidinones

Autor:innen und Institutionen

  • Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA 15213.
  • UCB Pharma, Braine-l'Alleud 1420, Belgium.
  • UCB Pharma, Cambridge, MA 02140.

ORCID-Profile: Matthew F Martin, Adrian Hall, Peter S Horanyi, Jonathan A Coleman

Förderung

  • Brain and Behavior Research Foundation (BBRF)

Zitieren

APA

Mittal, A., Martin, M. F., Provins, L., Hall, A., Ledecq, M., Wolff, C., Gillard, M., Horanyi, P. S., & Coleman, J. A. (2025). Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A). Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2510239122

Vancouver

Mittal A, Martin MF, Provins L, Hall A, Ledecq M, Wolff C, et al. Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A). Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2510239122

BibTeX
@article{Mittal2025,
  author = {Mittal, Anshumali and Martin, Matthew F and Provins, Laurent and Hall, Adrian and Ledecq, Marie and Wolff, Christian and Gillard, Michel and Horanyi, Peter S and Coleman, Jonathan A},
  title = {Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A)},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2510239122}
}
Kostenlos starten →